Swedish Orphan Biovitrum Ab
$14.7M 55 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Otsuka Pharmaceutical Development & Commercialization, Inc.
Otsuka Pharmaceutical Development & Commercialization, Inc. reported $14,762,929.16 across General Payments, Research, and Ownership to 4,515 physicians and teaching hospitals across 5,037 transactions.
- $14.8M Top 10% payer
- All-tracks total
- 5,037 Top quartile volume
- Transactions
- 4,515 Top quartile reach
- Recipients
- +$904.9K
- General Payments vs PY2023
Otsuka Pharmaceutical Development & Commercialization, Inc. reported $14,762,929.16 across all CMS Open Payments tracks (General + Research + Ownership) to 4,515 physicians and teaching hospitals in Program Year 2024 - ranking #127 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $3,518,683.40, averaging $3.3K per recipient.
How Otsuka Pharmaceutical Development & Commercialization, Inc.'s $14.8M all-tracks total breaks down
Otsuka Pharmaceutical Development & Commercialization, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
C
70/100
Total payments
A
100/100
Transaction volume
F
47/100
Physician reach
F
44/100
Payment type diversity
A
90/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer otsuka-pharmaceutical-development-commercialization-inc Otsuka Pharmaceutical Development & Commercialization, Inc.
$14.8M · #127/1,925 · 0.1% industry · PY2024
- TOT $14.8M
- RANK #127
- SHARE 0.1%
- TXN 5,037
- RCP 4,515
- CAT 7
- GEN $3.5M
- ΔGEN +$904.9K
- TOP1 13.0%
- PY 2024
Volume peers
Nearest volume peer: Swedish Orphan Biovitrum Ab ($14.7M)
Otsuka Pharmaceutical Development & Commercialization, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Otsuka Pharmaceutical Development & Commercialization, Inc.'s CMS-reported General Payments increased by $904.9K (+34.6%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.PY2023: OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.PY2024: Otsuka Pharmaceutical Development & Commercialization, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $2,613,745.97
- PY2024
- $3,518,683.40
What the Data Shows for Otsuka Pharmaceutical Development & Commercialization, Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Otsuka Pharmaceutical Development & Commercialization, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
480 transactions worth $2.9M make "Consulting Fee" the top general-payment category in the 7-category breakdown below, 83.3% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Otsuka Pharmaceutical Development & Commercialization, Inc. made 7 types of general payments. "Consulting Fee" is the largest category at $2.9M, 83.3% of General Payments.
Otsuka Pharmaceutical Development & Commercialization, Inc. reports 7 general-payment categories - the top three are Consulting Fee (83.3%), Food and Beverage (4.8%), and Compensation for Services Other Than Consulting (4.3%). The remaining 4 categories make up 7.6% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Otsuka Pharmaceutical Development & Commercialization, Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $2.9M | 480 | 83.3% |
| Food and Beverage | $167.9K | 3,520 | 4.8% |
| Compensation for Services Other Than Consulting | $149.9K | 103 | 4.3% |
| Grant | $145.0K | 4 | 4.1% |
| Travel and Lodging | $114.3K | 327 | 3.2% |
| Space Rental or Facility Fees | $7.7K | 2 | 0.2% |
| Education | $1.9K | 79 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $1,383,364.25 (39.3%) of $3,518,683.40 in this company's General Payments records across 2,948 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Otsuka Pharmaceutical Development & Commercialization, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Bruce Berger
$458,120.30 across 28 reported transactions
- 2
Linda Cappiello-Lindsley
$349,301.30 across 8 reported transactions
- 3
Hassan Malik
$253,953.54 across 14 reported transactions
- 4
Maryam Saba
$166,680.00 across 9 reported transactions
- 5
Haoling Weng
$155,309.11 across 6 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Otsuka Pharmaceutical Development & Commercialization, Inc. ranks #127 of 1,925 by total payments (top 7% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,359 of 1,838 by HHI (bottom 26% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Extremity Medical : $657.9K total payments, HHI 428
- 3-D Matrix, Inc. : $51.0K total payments, HHI 427
- Fisher Scientific Company L.L.C. : $185.9K total payments, HHI 424
- Becton, Dickinson and Company : $7.8M total payments, HHI 423
- DentalEZ, Inc. : $20.1K total payments, HHI 422
- Evoke Pharma, Inc. : $292.8K total payments, HHI 422
- Otsuka Pharmaceutical Development & Commercialization, Inc. (this company) : $3.5M total payments, HHI 421
- Boehringer Ingelheim International GmbH : $4.5M total payments, HHI 421
- Music City Medical Technologies, LLC : $11.8K total payments, HHI 420
- Reel Surgical, Inc. : $22.5K total payments, HHI 417
- Brainsway USA INC : $36.9K total payments, HHI 416
- Erbe USA Inc : $161.0K total payments, HHI 415
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Otsuka Pharmaceutical Development & Commercialization, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Otsuka Pharmaceutical Development & Commercialization, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Otsuka Pharmaceutical Development & Commercialization, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Roche Diagnostics Operations, Inc.
$14.9M 0 recipients
Compare payment profiles
Otsuka America Pharmaceutical, Inc.
$14.5M 186,436 recipients
Compare payment profiles
RxSight Inc
$14.5M 7,552 recipients
Compare payment profiles
NovApproach Spine, LLC
$14.5M 178 recipients
Compare payment profiles
Roche Molecular Systems, Inc.
$15.2M 813 recipients
Compare payment profiles
Put this to use
Otsuka Pharmaceutical Development & Commercialization, Inc. ranks #127 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where Otsuka Pharmaceutical Development & Commercialization, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Otsuka Pharmaceutical Development & Commercialization, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.